[A17-14] Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 03.07.2017
Project no.:
A17-14
Commission:
Commission awarded on 31.03.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-36 | Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14 | Commission completed |
| A23-114 | Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-95 | Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-108 | Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-109 | Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-113 | Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |